Abstract
Urinary bladder cancer is a worldwide health issue and the ninth most prevalent cancer across the globe, accounting for almost two-thirds of all urinary malignancies. Interleukin 17 (IL17) is a pro-inflammatory cytokine with pivotal modulatory effects on antitumor immune responses and has been reported to play a prominent role in the occurrence and development of bladder cancer. The present study aimed to measure the quantitative serum and urine levels of IL-17 in patients with bladder cancer. Blood and urine samples were obtained from 50 diagnosed bladder cancers and 96 healthy people as a control group. The serum and urine level of IL-17 was evaluated using an enzyme-linked immunosorbent assay. It has been revealed that the level of IL-17 was higher in all patients, as compared to that in controls. These results indicated that this interleukin is an indicator to predict the progression or recurrence of the disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
